Search

Simple Summary: We investigated the prognostic significance of the newly created Global Immune-Nutrition-Inflammation Index (GINI) in IIIC non-small cell lung cancer (NSCLC) patients who received definitive concurrent chemoradiotherapy (CCRT). A total of 802 newly diagnosed stage IIIC NSCLC patients were included. The optimal pre-CCRT GINI cutoff was 1562 (area under the curve: 76.1%; sensitivity: 72.4%; specificity: 68.2%; Youden index: 0.406). GINI ≥ 1562 was associated with significantly shorter median locoregional progression-free (p < 0.001), progression-free (p < 0.001), and overall survival (p < 0.001) than GINI < 1562. For each survival endpoint, the association between GINI and survival outcomes appeared independent of other confounding variables (p < 0.05 for each). The novel GINI index effectively stratified patients with stage IIIC NSCLSC into two distinct subgroups, demonstrating significant differences in both median and long-term survival rates. Background: We sought to determine the prognostic value of the newly developed Global Immune-Nutrition-Inflammation Index (GINI) in patients with stage IIIC non-small cell lung cancer (NSCLC) who underwent definitive concurrent chemoradiotherapy (CCRT). Methods: This study was conducted on a cohort of 802 newly diagnosed stage IIIC NSCLC patients who underwent CCRT. The novel GINI created first here was defined as follows: GINI = [C-reactive protein × Platelets × Monocytes × Neutrophils] ÷ [Albumin × Lymphocytes]. The receiver operating characteristic (ROC) curve analysis was used to determine the optimal pre-CCRT GINI cut-off value that substantially interacts with the locoregional progression-free (LRPFS), progression-free (PFS), and overall survival (OS). Results: The optimal pre-CCRT GINI cutoff was 1562 (AUC: 76.1%; sensitivity: 72.4%; specificity: 68.2%; Youden index: 0.406). Patients presenting with a GINI ≥ 1562 had substantially shorter median LRPFS (13.3 vs. 18.4 months; p < 0.001), PFS (10.2 vs. 14.3 months; p < 0.001), and OS (19.1 vs. 37.8 months; p < 0.001) durations than those with a GINI < 1562. Results of the multivariate analysis revealed that the pre-CCRT GINI ≥ 1562 (vs. <1562), T4 tumor (vs. T3), and receiving only 1 cycle of concurrent chemotherapy (vs. 2–3 cycles) were the factors independently associated with poorer LRPS (p < 0.05 for each), PFS (p < 0.05 for each), and OS (p < 0.05 for each). Conclusion: The newly developed GINI index efficiently divided the stage IIIC NSCLSC patients into two subgroups with substantially different median and long-term survival outcomes. [ABSTRACT FROM AUTHOR]

Considering the high rates of long-term survival in breast cancer patients, it is crucial to determine the most appropriate RT technique in order to prevent RT-related heart and lung damage and other complications that may adversely affect quality of life. In this study, we aimed to detect the superior radiotherapy technique in patients with breast cancer in terms of the target volumes and the organ at risk (OAR). We included 20 breast cancer patients who were applied modified radical mastectomy. Two different treatment plans (IMRT and 3DCRT) were prepared for each patient. Chest wall, supraclavicular, axillary and/or mammaria interna lymphatic regions were contoured as clinical target volüme (CTV). For planning target volüme (PTV), 0.5 cm was added to CTV (post margin; 0.3 cm). The doses of the target volumes and the OAR volumes (contralateral breast, heart, ipsilateral lung), the homogeneity index (HI) were compared. For the heart, the contralateral breast, the ipsilateral lung, Dmean and V25, Dmean and Dmax, D5 and D20 were evaluated, respectively. In addition, D2, D98, D95 ve Dmean were investigated for the PTV. Mann Whitney test was used for statistical analysis and p< 0.05 was considered significant. IMRT technique was superior to the 3DCRT in terms of the PTV, the OAR volumes and the HI. However, irradiated contralateral breast volume was less in the 3DCRT technique. [ABSTRACT FROM AUTHOR]